Dermata Therapeutics Faces Nasdaq Delisting Following Failure to Meet Stockholder's Equity Requirement and Minimum Bid Price Requirement

Strategic Insights -

Dermata Therapeutics, Inc. has found itself in a precarious position as it struggles to comply with the minimum stockholders' equity requirement and minimum bid price requirement to maintain its listing on the Nasdaq Capital Market. The company received a notice from the Nasdaq Listing Qualifications Department indicating that it no longer meets the stockholders' equity requirement, but it regained compliance on May 14, 2025. However, it failed to meet the minimum bid price requirement and will be subject to delisting unless it requests a hearing before the Nasdaq Hearings Panel by May 21, 2025. The company plans to request a hearing, but there is no guarantee it will regain compliance or maintain its listing.

Key Takeaways:

  • Dermata Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department on May 14, 2025, stating it no longer met the minimum stockholders' equity requirement.
  • The company regained compliance with the stockholders' equity requirement on May 14, 2025, but faces delisting due to failing to meet the minimum bid price requirement.
  • Dermata Therapeutics will request a hearing before the Nasdaq Hearings Panel to appeal the decision and avoid delisting.
  • If the company's compliance plan is not accepted, or if it fails to regain compliance, its securities may be subject to delisting.
  • The company's common stock will be suspended from trading on May 23, 2025, unless the Nasdaq Hearings Panel grants an extension.
  • Gerald T. Proehl, Chief Executive Officer, signed the report on May 16, 2025.

Statistics:

  • May 14, 2025: Date of the Nasdaq Listing Qualifications Department notice regarding failure to meet the stockholders' equity requirement.
  • May 14, 2025: Date when Dermata Therapeutics regained compliance with the stockholders' equity requirement.
  • May 21, 2025: Deadline for the company to request a hearing before the Nasdaq Hearings Panel to avoid delisting.
  • May 23, 2025: Date when the company's common stock will be suspended from trading if the Nasdaq Hearings Panel does not grant an extension.

Sources:

  • United States Securities and Exchange Commission FORM 8-K (Current Report)

* Nasdaq Listing Rule 5550(a)(2)

* Nasdaq Listing Rule 5550(b)(1)

* Securities Exchange Act of 1934

* Private Securities Litigation Reform Act of 1995

* Dermata Therapeutics, Inc. Annual Report on Form 10-K